Sector: Pharma
ZA_APN
Net debt (table and EV/EBITDA): |short-term borrowings| + |long-term borrowings| + |other financial liabilities| when extracted + |non-controlling interest| when extracted − |cash and equivalents|; amounts in millions of the reporting currency.
Shares: yahoo_fundamentals_timeseries/APN.JO
Monetary columns are in M USD, one decimal; scale (K/M/B/T) keeps values readable. For the period (default) shows P&L and cash flow for that row’s reporting window: quarterly amounts when the feed uses quarter-duration facts (typical US 10-Q revenue and income), quarterly cash flows after stripping YTD where only cumulative tags exist, and an implied Q4 on 31 Dec FY rows (P&L: FY minus Q1–Q3; operating / investing cash flow: FY 12m minus 9M YTD to 30 Sep when sourced from SEC builder evidence) so they match 10-Q scale. Some issuers still use cumulative YTD minus the prior row in the same calendar year. As reported shows values stored on each row (e.g. full-year on FY). Balance sheet is always as reported. Source JSON may use millions etc.; conversion uses amounts_unit per row.
| Date | Period | Status | RevenueM USD | Operating profitM USD | D&AM USD | EBITDAM USD | Net profitM USD | Operating CFM USD | Capex + M&AM USD | AssetsM USD | EquityM USD | ROE (annualized) | Net debtM USD | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | H1 2025 (6M) | OK | -1400.6 y/y — | -367.1 y/y — | -60.0 y/y — | -427.1 y/y — | 141.6 y/y — | -79.9 | 3927.0 | 7737.8 y/y — | 4900.1 y/y — | 3.4% | 27323.0 | Link |
| 2025-06-30 | FY 2025 (12M) | OK | 2359.3 y/y -1.9% | 469.3 y/y -16.5% | 113.7 y/y 7.0% | 582.9 y/y -12.8% | -58.9 y/y -124.9% | 280.7 | -5055.0 | 7642.0 y/y 0.1% | 4774.0 y/y 2.5% | -1.2% | 29210.0 | Link |
| 2024-06-30 | FY 2024 (12M) | OK | 2405.9 y/y 6.7% | 562.2 y/y 23.1% | 106.2 y/y 7.2% | 668.3 y/y 20.3% | 237.0 y/y -18.1% | 335.0 | -5535.0 | 7635.4 y/y 7.7% | 4659.4 y/y 2.3% | 5.1% | 23522.0 | Link |
| 2023-06-30 | FY 2023 (12M) | OK | 2254.1 y/y — | 456.6 y/y — | 99.0 y/y — | 555.6 y/y — | 289.5 y/y — | 305.6 | -3181.0 | 7090.7 y/y — | 4553.6 y/y — | — | 18207.0 | Link |
Quarterly values (ZAR mln)
Year-over-year change
FCF (ZAR mln)
Net debt / cash (ZAR mln)
Value the company creates per year, as a % of market cap
Value created per year: -153.2%
| 1. EBITDA growth (latest quarter YoY, annualised) [EBITDA latest qtr − EBITDA year-ago qtr] × annualisation X = — | -85 |
| 2. Current EV/EBITDA (LTM) (Market cap + Net debt) ÷ EBITDA (LTM) = (4 175 + 27 323) ÷ 583 | 30.0x — capped at 30x |
| 3. Target multiple (Current EV/EBITDA + 8) ÷ 2 = (30.0 + 8) ÷ 2 | 19.0x |
| 4. Cash flow (balance method, LTM) Net-debt reduction + dividends + buybacks − equity issuance = -3 801 + 0 + 0 − 0 | -4 774 |
| 5. Value created per year (EBITDA growth × Target multiple + Cash flow − Dilution) ÷ Market cap = (-85 × 19.0 + -4 774) ÷ 4 175 | -153.2% |
Amounts in millions of the reporting currency. EBITDA growth is the latest quarter vs the same quarter a year ago, annualised.
Caveats:
| Date | Per share | Details | Status | Source |
|---|---|---|---|---|
| 2025-10-01 | 211 ZAR | Ex-dividend: 211 ZAR per share | Paid | Yahoo Finance (ex-div) |
| 2024-09-18 | 359 ZAR | Ex-dividend: 359 ZAR per share | Paid | Yahoo Finance (ex-div) |
| 2023-09-20 | 342 ZAR | Ex-dividend: 342 ZAR per share | Paid | Yahoo Finance (ex-div) |
| 2022-09-21 | 326 ZAR | Ex-dividend: 326 ZAR per share | Paid | Yahoo Finance (ex-div) |
| 2021-09-21 | 262 ZAR | Ex-dividend: 262 ZAR per share | Paid | Yahoo Finance (ex-div) |
KASE: status follows wording in the news headline (paid vs intends to pay). Yahoo: amounts are cash dividends per share on ex-dividend dates (UTC calendar date). stockscope.uz (UZ): amounts are per share in UZS by publication date (not necessarily ex-div).
Investor reporting (IR): https://www.aspenpharma.com/investor-relations/
Reporting forms detected in loaded periods: ✓ ✓ ✓ (Balance sheet / Profit or loss (P&L) / Cash flows)